Cargando…

Research progress on non-protein-targeted drugs for cancer therapy

Non-protein target drugs, especially RNA-based gene therapies for treating hereditary diseases, have been recognized worldwide. As cancer is an insurmountable challenge, no miracle drug is currently available. With the advancements in the field of biopharmaceuticals, research on cancer therapy has g...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Yiwen, Lu, Lu, Song, Feifeng, Zou, Xiaozhou, Liu, Yujia, Zheng, Xiaowei, Qian, Jinjun, Gu, Chunyan, Huang, Ping, Yang, Ye
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10011800/
https://www.ncbi.nlm.nih.gov/pubmed/36918935
http://dx.doi.org/10.1186/s13046-023-02635-y
Descripción
Sumario:Non-protein target drugs, especially RNA-based gene therapies for treating hereditary diseases, have been recognized worldwide. As cancer is an insurmountable challenge, no miracle drug is currently available. With the advancements in the field of biopharmaceuticals, research on cancer therapy has gradually focused on non-protein target-targeted drugs, especially RNA therapeutics, including oligonucleotide drugs and mRNA vaccines. This review mainly summarizes the clinical research progress in RNA therapeutics and highlights that appropriate target selection and optimized delivery vehicles are key factors in increasing the effectiveness of cancer treatment in vivo.